The use of recombinant activated factor VII to control bleeding during repair of a suprarenal abdominal aortic aneurysm.
Recombinant activated factor VII (rFVIIa) was first used to control bleeding in haemophilia patients. More recently, it has been used to prevent severe bleeding in patients without pre-existing coagulopathy. We report a case where rFVIIa was used to successfully control postoperative bleeding in a patient undergoing suprarenal abdominal aortic aneurysm (AAA) repair.
Wahlgren
C-M
CM
Department of Vascular Surgery, Karolinska Hospital, 171 76 Stockholm, Sweden.
Swedenborg
J
J
D017544:Aortic Aneurysm, Abdominal / Q000601:surgery*; D016063:Blood Loss, Surgical; D015942:Factor VIIa / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D015942:Factor VIIa